Contact us

Thank you for your interest in Garg Law PLLC.

Our commitment to understanding your regulatory questions and business goals, and helping you achieve results starts here.

If you are looking for representation on a new matter, please fill out the form below to request a free consultation. The form enables us to conduct a preliminary check for potential conflicts of interest and to determine if we can proceed with the free consultation.

INSIGHTS

When FDA Problems Become Customs Claims

Mitigating Liquidated Damages

Wondering what liquidated damages actually are? They’re a predetermined sum written into your customs bond that CBP can assess when a bond condition isn’t met, with no need to prove actual harm.

Here’s the twist for FDA-regulated importers: you may have already thought you dealt with the FDA problem, and the bill can still show up. Your shipment was refused, exported, or destroyed, and you moved on. Then an envelope arrives from U.S. Customs and Border Protection (CBP), and this one has a dollar figure on it.

How an FDA Problem Becomes a Customs Claim

FDA-regulated goods are often released under a customs bond. Among other things, the bond obligates you to return the merchandise to CBP on demand and to meet any conditions imposed to bring the product into compliance with FDA requirements. Miss one, and CBP may treat it as a breach and assess liquidated damages.

The good news: the amount demanded is not necessarily the amount owed. Under 21 C.F.R. § 1.97, CBP may cancel liability in full, accept a lesser amount, or grant relief on other appropriate terms once you apply for it. For an FDA-related bond, however, CBP cannot act without the agreement of the FDA division director. That makes two agencies to persuade—twice the audience and half the applause!

Prevention Beats Petitioning

The best mitigation starts before the shipment reaches the border. It is important to treat FDA and customs compliance as one function, not two silos that only talk when something goes wrong. In practice, that means:

  • Review admissibility before you ship, not after a detention notice arrives.
  • Hold the goods when FDA asks for a sample. FDA regulations direct the owner or consignee not to distribute the article until further notice about the examination.
  • Respond quickly whenever FDA or CBP restricts distribution or demands corrective action.
  • Consider whether the product can be fixed. FDA regulations allow you to apply for authorization to relabel or recondition an inadmissible import, which can be a better outcome than export or destruction.

It also pays to have a written escalation plan for detained or refused merchandise. This includes deciding in advance who receives FDA and CBP notices, who talks to your customs broker and surety, who has the authority to stop distribution, and who keeps the proof of exportation, destruction, or redelivery. As we like to say, if it’s not in writing, it doesn’t exist.

If the Claim Has Already Arrived

CBP issues Form 5955A, and you generally have 60 calendar days from issuance to petition for relief. Start by reconstructing what FDA and CBP required, how and when you responded, what happened to the goods, what records prove it, why the breach occurred, and what controls now prevent a repeat.

Section 1.97 turns on what is appropriate “in view of the circumstances,” and along with CBP’s mitigation guidelines, demonstrate that the facts are critical for the bases of the petition. A strong petition advocates to reduce or cancel the claim, and is not a plea for leniency.

The Takeaway

An FDA import problem and a CBP liquidated damages claim are related, but they are not the same problem. A business can prevent the first with disciplined import controls, and answer the second with a disciplined factual and legal record. If a claim does arrive, don’t assume the face amount is final.

Garg Law helps importers evaluate FDA-related liquidated damages claims, construct the underlying import and regulatory record, develop mitigation arguments, and prepare petitions for relief. Our goal is simple: understand what happened, address the government’s concerns, and make the strongest supportable case for reducing or eliminating the claim. For assistance with liquidated damage cases or for questions on FDA compliance or enforcement, please email info@garg-law.com.

★★★★★

Working with Shelly on various new product launches over the last couple of years has been seamless. Quick and clear guidance is always what we get.
R.G. Client
I've been working with Shelly and her team at Garg law for a little while now and they are fantastic! Very responsive, professional and they certainly get things done. Extremely satisfied with their service and highly recommend.
Mike H. Client
Ms Garg helped my company navigate an FDA import issue. She achieved an excellent result, was very responsive and professional, and managed to keep the project within budget. She is a stellar attorney.
Dr. Sastry Client
I have been using Shelly Garg as FDA Counsel for 10+ years, since she was at another international law firm. While we continued to use the previous firm she was at (mainly due to the process required to change firms), we realized the quality of counsel was not the same. We have since been using Garg Law and the ease of use and trust in the knowledge was back instantly. Shelly has the skills to help me understand the regulations (by translating into layman's terms) and risks in a manner that is specific to my business. She is also extremely timely in her responses which is critical when we have a deadline mandated by the FDA. Many other attorneys cite the regulations which l've already read, but need further counsel. In my opinion, this demonstrates Shelly's in-depth knowledge of the regulations, how they pertain to the law, and how they are applicable IRL. Shelly's personable approach and pleasant manner in communication makes it very easy to have been work with her and have productive discussions on the best next steps. She truly has a passion iternational for all things FDA and I've learned so much from her.
Claire P. Client

News & Insights

Get the latest news on FDA regulatory delivered straight to your inbox.